Other Events ·
Keros Therapeutics doses first patient in Phase 2 trial of rinvatercept for Duchenne muscular dystrophy
KROSKeros Therapeutics, Inc.
Keros Therapeutics, Inc. announced on September 28, 2026, that the first patient was dosed in its Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD). The open-label, multi-cohort basket trial aims to assess safety, tolerability, pharmacokinetics, and functional improvements in late-ambulatory and early non-ambulatory patients. Initial data from this study is expected in the first half of 2027. Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.